title: Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment.
abstract: 1. The major side effects of the immunosuppressive drug cyclosporin A (CsA) are hypertension and nephrotoxicity. It is likely that both are caused by local vasoconstriction. 2. We have shown previously that 20 h treatment of rat vascular smooth muscle cells (VSMC) with therapeutically relevant CsA concentrations increased the cellular response to [Arg8]vasopressin (AVP) by increasing about 2 fold the number of vasopressin receptors. 3. Displacement experiments using a specific antagonist of the vasopressin V1A receptor (V1AR) showed that the vasopressin binding sites present in VSMC were exclusively receptors of the V1A subtype. 4. Receptor internalization studies revealed that CsA (10(-6) M) did not significantly alter AVP receptor trafficking. 5. V1AR mRNA was increased by CsA, as measured by quantitative polymerase chain reaction. Time-course studies indicated that the increase in mRNA preceded cell surface expression of the receptor, as measured by hormone binding. 6. A direct effect of CsA on the V1AR promoter was investigated using VSMC transfected with a V1AR promoter-luciferase reporter construct. Surprisingly, CsA did not increase, but rather slightly reduced V1AR promoter activity. This effect was independent of the cyclophilin-calcineurin pathway. 7. Measurement of V1AR mRNA decay in the presence of the transcription inhibitor actinomycin D revealed that CsA increased the half-life of V1AR mRNA about 2 fold. 8. In conclusion, CsA increased the response of VSMC to AVP by upregulating V1AR expression through stabilization of its mRNA. This could be a key mechanism in enhanced vascular responsiveness induced by CsA, causing both hypertension and, via renal vasoconstriction, reduced glomerular filtration.
authors.affiliation: Pharmacology Group, School of Pharmacy, University of Lausanne, BEP, 1015 Lausanne, Switzerland.
authors.forename: F
authors.initials: F
authors.lastname: Cottet-Maire
authors.forename: P V
authors.initials: PV
authors.lastname: Avdonin
authors.forename: E
authors.initials: E
authors.lastname: Roulet
authors.forename: T M
authors.initials: TM
authors.lastname: Buetler
authors.forename: N
authors.initials: N
authors.lastname: Mermod
authors.forename: U T
authors.initials: UT
authors.lastname: Ruegg
mesh_terms: D000818:Animals; D001127:Arginine Vasopressin / Q000378:metabolism; D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology*; D000081035:Heterogeneous Nuclear Ribonucleoprotein D0; D034502:Heterogeneous-Nuclear Ribonucleoprotein D; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D016601:RNA-Binding Proteins / Q000502:physiology; D051381:Rats; D011921:Rats, Inbred WKY; D017483:Receptors, Vasopressin / Q000096:biosynthesis / Q000187:drug effects* / Q000235:genetics; D015854:Up-Regulation
chemical_list: D000081035:Heterogeneous Nuclear Ribonucleoprotein D0; D034502:Heterogeneous-Nuclear Ribonucleoprotein D; C000630988:Hnrnpd protein, rat; D007166:Immunosuppressive Agents; D012333:RNA, Messenger; D016601:RNA-Binding Proteins; D017483:Receptors, Vasopressin; D001127:Arginine Vasopressin; D016572:Cyclosporine